Conditions

close

result 5666 件

Author Ogino, Atsuko|
Published Date 2008-06-30
Publication Title
Content Type Thesis or Dissertation
Author Kobuke, Makoto| Nasu, Yasutomo| Kumon, Hiromi|
Published Date 2008-08-01
Publication Title 岡山医学会雑誌
Volume volume120
Issue issue2
Content Type Journal Article
Author Otsuka, Masaki| Asagoe, Kenji| Iwatsuki, Keiji|
Published Date 2008-08-01
Publication Title 岡山医学会雑誌
Volume volume120
Issue issue2
Content Type Journal Article
Author Tominaga, Susumu|
Published Date 2008-08-01
Publication Title 岡山医学会雑誌
Volume volume120
Issue issue2
Content Type Journal Article
Author Chayama, Kosuke|
Published Date 2008-08-01
Publication Title 岡山医学会雑誌
Volume volume120
Issue issue2
Content Type Journal Article
Author Shinagawa, Katsuji|
Published Date 2008-08-01
Publication Title 岡山医学会雑誌
Volume volume120
Issue issue2
Content Type Journal Article
Author Tsunemitsu, Yosuke| Inagaki, Masaru| Hamano, Ryosuke| Nishie, Manabu| Tokunaga, Naoyuki| Otsuka, Shinya| Osaki, Toshihide| Iwagaki, Hiromi|
Published Date 2008-08-01
Publication Title 岡山医学会雑誌
Volume volume120
Issue issue2
Content Type Journal Article
Title Alternative Adult neural stem and progenitor cell transplantation in CNS diseases
FullText URL 120_153.pdf
Author Kameda, Masahiro| Shingo, Tetsuro| Muraoka, Kenichiro| Takahashi, Kazuya| Yasuhara, Takao| Date, Isao|
Keywords 成体由来神経幹細胞 脳内移植 グリア細胞株由来神経栄養因子(GDNF) 脳虚血 パーキンソン病
Publication Title 岡山医学会雑誌
Published Date 2008-08-01
Volume volume120
Issue issue2
Start Page 153
End Page 157
ISSN 00301558
language Japanese
Copyright Holders 岡山医学会
File Version publisher
DOI 10.4044/joma.120.153
NAID 120002310550
Author Nasu, Yasutomo|
Published Date 2008-08-01
Publication Title 岡山医学会雑誌
Volume volume120
Issue issue2
Content Type Journal Article
Author Kataoka, Hitomi| Shikata, Kenichi| Sasaki, Motofumi| Makino, Hirofumi|
Published Date 2008-08-01
Publication Title 岡山医学会雑誌
Volume volume120
Issue issue2
Content Type Journal Article
Author Edamura, Kohei|
Published Date 2008-08-01
Publication Title 岡山医学会雑誌
Volume volume120
Issue issue2
Content Type Journal Article
Author Yagi, Toru| Kawahara, Yoshiro| Okada, Hiroyuki| Takemoto, Koji| Kato, Jun| Kobayashi, Yoshiyuki| Kawamoto, Hirofumi| Yamamoto, Kazuhide|
Published Date 2008-01-04
Publication Title 岡山医学会雑誌
Volume volume119
Issue issue3
Content Type Journal Article
Author Sano, Yoshifumi|
Published Date 2008-01-04
Publication Title 岡山医学会雑誌
Volume volume119
Issue issue3
Content Type Journal Article
Author Kiura, Katsuyuki| Takigawa, Nagio| Oze, Isao| Yasugi, Masayuki| Ochi, Nobuaki| Harada, Daijiro| Tanimoto, Mitsune|
Published Date 2008-01-04
Publication Title 岡山医学会雑誌
Volume volume119
Issue issue3
Content Type Journal Article
Author Doihara, Hiroyoshi| Taira, Naruto|
Published Date 2008-01-04
Publication Title 岡山医学会雑誌
Volume volume119
Issue issue3
Content Type Journal Article
Author Cui, Jinhua|
Published Date 2008-01-04
Publication Title 岡山医学会雑誌
Volume volume119
Issue issue3
Content Type Journal Article
Author Kajiya, Masahito|
Published Date 2008-01-04
Publication Title 岡山医学会雑誌
Volume volume119
Issue issue3
Content Type Journal Article
Author Miyazaki, Ikuko| Asanuma, Masato| Francisco J. Diaz-Corrales| Miyoshi, Ko| Ogawa, Norio|
Published Date 2008-01-04
Publication Title 岡山医学会雑誌
Volume volume119
Issue issue3
Content Type Journal Article
Title Alternative Adenoviral p53 gene therapy for lung cancer
FullText URL 119_229.pdf
Author Fujiwara, Toshiyoshi| Tanaka, Noriaki|
Abstract To determine the feasibility, safety, humoral immune response, and biological activity of multiple intratumoral injections of Ad5CMV-p53, and to characterize the pharmacokinetics of Ad5CMV-p53 in patients with advanced non-small cell lung cancer (NSCLC). Fifteen patients with histologically confirmed NSCLC and p53 mutations were enrolled into this phase I trial. Nine patients received escalating dose levels of Ad5CMV-p53 (1 × 109 to 1 × 1011 plaque-forming units[PFU]) as monotherapy once every 4 weeks. Six patients were treated on a 28-day schedule with Ad5CMV-p53 in combination with intravenous administration of cisplatin (80 mg/m2). Patients were monitored for toxicity, vector distribution, antibody formation, and tumor response. Fifteen patients received a total of 63 intratumoral injections of Ad5CMV-p53 without dose-limiting toxicity. The most common treatment-related toxicity was a transient fever. Specific p53 transgene expression was detected using reverse-transcriptase polymerase chain reaction in biopsied tumor tissues throughout the period of treatment despite of the presence of neutralizing anti-adenovirus antibody. Distribution studies revealed that the vector was detected in the gargle and plasma, but rarely in the urine. Thirteen of 15 patients were assessable for efficacy; one patient had a partial response (squamous cell carcinoma at the carina), 10 patients had stable disease, with three lasting ≥9 months, and 2 patients had progressive disease. Multiple courses of intratumoral Ad5CMV-p53 injection alone or in combination with intravenous administration of cisplatin were feasible and well tolerated in advanced NSCLC patients, and appeared to provide clinical benefit.
Keywords p53 遺伝子 アデノウイルスベクター (adenovirus vector) 肺癌 (lung cancer) 臨床試験 (clinical trial)
Publication Title 岡山医学会雑誌
Published Date 2008-01-04
Volume volume119
Issue issue3
Start Page 229
End Page 234
ISSN 00301558
language Japanese
Copyright Holders 岡山医学会
File Version publisher
DOI 10.4044/joma.119.229
NAID 10020282723
Author Sunahori, Katsue| Yamamura, Masahiro| Yamana, Jiro| Takasugi, Koji| Makino, Hirofumi|
Published Date 2008-01-04
Publication Title 岡山医学会雑誌
Volume volume119
Issue issue3
Content Type Journal Article